Skip to main content
S&P 5007,520.93-0.38%DOW52,231.89-0.30%NASDAQ25,065.88-0.74%BTC$73,768.00-0.06%ETH$2,056.30-0.62%GOLD$4,043.80+0.34%OIL$87.00+1.12%
Smart Investors Daily
SID Premium
Bausch Health Companies Inc. logo

NYSE · BHC

Bausch Health Companies Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$8.29

Down-$0.11 (-1.30%)

Updated Nov 11, 2026, 1:31 PM

SID Score

7.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.6B
P/E ratio
7.19
Dividend yield
0.00%
52-week range
$4.33 – $9.04
Volume
2.45M
Avg. volume
2.36M

Price performance · BHC

BHC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 10, 2026

BHC closed at $8.29 after 21 trading sessions, up 40.75% for the selected period.

Last close
$8.29
Period change
+40.75%
Period low
$5.89
Period high
$8.91
Daily close
View OHLC price history
BHC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 10, 2026$8.39$8.39$8.155$8.292.45M
Nov 9, 2026$8.192$8.56$8.192$8.403.95M
Nov 6, 2026$7.86$8.195$7.86$8.183.07M
Nov 5, 2026$8.34$8.375$7.96$7.963.34M
Nov 4, 2026$8.28$8.46$8.225$8.343.53M
Nov 3, 2026$7.96$8.18$7.87$8.143.42M
Nov 2, 2026$8.21$8.345$7.955$8.024.94M
Oct 30, 2026$8.93$9.04$8.175$8.208.87M
Oct 29, 2026$7.66$9.04$7.58$8.9133.78M
Oct 28, 2026$6.29$6.97$6.25$6.928.07M
Oct 27, 2026$6.37$6.37$6.225$6.311.56M
Oct 26, 2026$6.53$6.55$6.27$6.352.4M
Oct 23, 2026$6.44$6.49$6.2012$6.442.43M
Oct 22, 2026$6.43$6.505$6.405$6.491.2M
Oct 21, 2026$6.40$6.515$6.29$6.452.03M
Oct 20, 2026$6.42$6.54$6.36$6.422.03M
Oct 19, 2026$6.27$6.42$6.25$6.321.35M
Oct 16, 2026$6.35$6.385$6.20$6.302.19M
Oct 15, 2026$5.95$6.35$5.95$6.312.31M
Oct 14, 2026$5.89$6.05$5.85$5.891.75M
Oct 13, 2026$5.91$5.92$5.732$5.891.56M

Latest BHC news

The latest Smart Investors Daily articles mentioning BHC.

Stock researchCompany · Overview

BHC research

Overview

Company profile and research snapshot.

Company profile

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.00
Implied upside
—
Analysts
—
BHC recent ratings
DateFirmRatingTarget
Aug 4, 2026TD COWENHold—
May 1, 2026TRUIST SECURITIESHold—
Apr 30, 2026TRUIST SECURITIESHold—
Apr 30, 2026TD COWENHold—
Apr 29, 2026TD COWENHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 6, 2026

Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026

Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting® 2026, November 5–9 in Denver, Colorado. The study highlights the substantial mortality and rehospitalization among patients hospitalized with severe alcohol-associated hepatitis (AH).

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By